The E7 protein encoded by human papillomavirus type 16 shows transforming and immortalizing activities which are mediated, in part, through the interaction of the viral oncoprotein with the pRB protein family. This interaction is not solely responsible for E7 function, however, and other properties of E7, such as the interaction with basal transcription factors such as TBP, are likely to be of importance. We show here that three regions of the viral protein contribute to the interaction between E7 and TBP ; the pRB-binding domain, the casein kinase II phosphorylation region and the C-terminal dimerization domain. Mutations within each region reduced the interaction of E7 with TBP in vitro, and simultaneous alterations within each of these regions completely abrogated binding. Unlike the pRB interaction, the association of E7 with TBP was enhanced following phosphorylation of E7 by casein kinase II, demonstrating a functional significance for phosphorylation of the viral protein.
yet unknown activities, are also required for full biological function (Vousden, 1994) .
The HPV-16 E7 open reading frame encodes a 98 amino acid phosphoprotein which shows some structural homology to transforming proteins from simian virus (SV) 40 and adenovirus (LT and E1A), including the region which mediates the interaction between the viral oncoproteins and the pRB pocket-protein family (Vousden, 1995) . Although interaction with the pRB pocket proteins is clearly important, mutagenic analyses of E7 have identified several regions of the protein, other than the pRB binding domain, as necessary for full E7 function (Vousden, 1994) . These include the C-terminal zincbinding domain, which plays a role in dimerization and protein stability, the casein kinase II phosphorylation sites adjacent to the pRB binding domain and the N terminus of E7, which has no known function.
In addition to activating E2F-dependent transcription, both E7 and E1A show evidence of E2F-independent transcriptional activity (Edmonds & Vousden, 1989 ; Rawls et al., 1990) which is not shared by LT (Wong & Ziff, 1996) . Some of the transcriptional functions of E1A are related to the interaction with p300, a cellular protein which functions as a co-activator (Arany et al., 1994 ; Lundblad et al., 1995) . There is, however, no evidence of a similar interaction between E7 and p300. E1A has also been shown to interact with some of the components of the transcription factor TFIID, including TAF II 110 and the DNA-binding component, TBP. The interaction with TFIID contributes to the transcriptional activity of E1A (Geisberg et al., 1994 ; Lee et al., 1991) , and although the principal interaction occurs through E1A CR3 sequences, which have no clear equivalent in E7, TBP also shows a weaker interaction with E1A proteins lacking CR3 (Lee et al., 1991 ; Mazzarelli et al., 1995) . E7 has recently also been shown to interact with TBP and TAF II 110 (Mazzarelli et al., 1995) , raising the intriguing possibility that the ability to transactivate genes by functioning as a recruitable transactivating domain may be a common strategy of DNA tumour viruses.
Analysis of the interaction between HPV-16 E7 and TBP was carried out using in vitro translated E7 proteins (Barbosa et al., 1990) and GST-TBP fusion proteins produced in bacteria (Hagemeier et al., 1992) which were purified as previously described (Bannister et al., 1991 published data, an interaction was detected between wild-type E7 and TBP and use of fusion proteins containing fragments of TBP showed clearly that this interaction was entirely dependent on the C terminus of TBP, an N-terminal TBP-GST fusion protein showing no detectable interaction with any E7 protein tested (Fig. 1 a) . This result is consistent with other transcription factors, which have also been demonstrated to bind to the C terminus of TBP (Hagemeier et al., 1994) . In order to identify the E7 sequences which participate in this interaction, we initially analysed a series of previously described E7 point mutants ( Fig. 1 b) for their ability to bind TBP and found that all of the mutants show some degree of binding, with respect to the GST-alone control (Fig. 1 a) . Analysis of proteins carrying point mutations within the region of homology to E1A CRII, including E7-24GLY and E7-26GLY, which specifically interfere with pRB binding, and E7-31\32ARG\PRO, which results in the substitution of the two serine residues phosphorylated by the casein kinase II for non-phosphorylatable amino acids without impinging on pRB binding, indicated reduced TBP-binding. The E7-58\91GLY\ GLY mutant, which carries substitutions in the cysteine residues necessary for E7 dimerization, also showed a decrease in affinity for TBP. The reduced binding efficiency of these point mutants is modest, but clearly reproducible. E7 point mutants which failed to show any defect in TBP binding were E7-21SER and E7-71ILE, which are also wild-type for other E7 functions, and E7-2PRO, which is transformation incompetent despite retaining a functional pRB binding activity (Banks et al., 1990) .
Previous studies have shown that both pRB binding and casein kinase II phosphorylation contribute to E7 biological activity. We therefore analysed a deletion mutant, E7-∆21-35, in which both domains are lost, and HPV-11 E7, which binds pRB much more weakly and is less efficiently phosphorylated than HPV-16 E7. Although both of these E7 proteins showed reduced binding, there was clearly some binding above background levels (Fig. 1 c) .
None of the E7 point mutants tested showed complete loss of TBP binding, although the reduced binding seen with proteins carrying mutations in the pRB binding\ phosphorylation region and the cysteine residues in the C terminus suggested that both of these regions of the E7 protein may contribute to the interaction with TBP. The C-terminal E7-58\91GLY\GLY mutant is unable to dimerize and the overall structural integrity of the protein is likely to be affected, as these residues coordinate the zinc ion within the zinc-loop structure (Clemens et al., 1995 ; McIntyre et al., 1993) . As a consequence, the C terminus of E7 might contribute to TBPbinding indirectly, by providing a dimerization domain and ensuring conformational integrity of the protein. Alternatively, the C terminus of E7 may contain residues that directly make contacts with the TBP. To distinguish between these possibilities, two E7 deletion mutants were generated by PCR using forward primers which truncated the 5h E7 sequences and introduced a methionine codon to generate proteins encoding E7 sequences from amino acids 18-98 or 37-98. These mutants were tested for TBP binding (Fig. 2) . Deletion of the first 18 N-terminal amino acids did not affect TBP binding and although deletion of the first 37 amino acids, including the pRB and casein kinase II phosphorylation sites, caused a severe reduction in TBP binding, some binding capacity was retained, suggesting that the C terminus of E7 contains an independent TBP-binding domain. Introduction of the two point mutants at cysteine residues 58 and 91 into the C-terminal 37-98 fragment of E7 completely abolished TBP binding and the full-length E7 protein carrying the small deletion of residues 21-35 and the double cysteine substitutions at residues 58 and 91 was also completely unable to bind TBP (Fig. 2) . These results suggest that E7 contains two independent TBP-binding regions and the identification of mutants within both which are binding defective supports the specificity of the wild-type E7\TBP interaction in this in vitro assay.
The principal TBP-binding activity of E7 depended on the integrity of sequences between residues 21-35, including the pRB-binding domain. Clearly, the TBP interaction did not correlate entirely with pRB binding since both the E7-24GLY and E7-26GLY mutants, which do not bind pRB, still retained significant TBP-binding activity (Fig. 1) . The casein kinase II phosphorylation site is also within this region and mutation of the phosphoacceptor sites (serines 31 and 32) resulted in a small reduction in the capacity to bind TBP (Fig. 1) . We therefore investigated the effect of phosphorylation at these residues on the interaction of E7 with TBP (Fig. 3) . As shown previously (Barbosa et al., 1990 ) serines 31 and 32 in HPV-16 E7 can be phosphorylated by casein kinase II and mutation of both of these sites results in the production of an E7 protein which was not phosphorylated (Fig. 3 a) . Phosphorylation of wild-type E7 by casein kinase II significantly enhanced the efficiency of binding to TBP, compared to E7 protein which was not pre-incubated with the kinase (Fig. 3 b) . As seen before, specific substitution of the phosphorylated serines (31\32) somewhat reduced TBP binding compared to wild-type E7 and the binding of this unphosphorylatable E7 mutant was not enhanced by incubation with casein kinase II (Fig. 3 b) . Similarly, the inefficient binding of the deletion mutant E7-∆21-35 (in which both pRB and CKII sites are deleted) was not enhanced by casein kinase II. TBP binding of HPV-11 E7, which is less efficiently phosphorylated by casein kinase II, was only slightly enhanced by treatment with the kinase (Fig. 3 b) .
The interaction of E7 with TBP, first described by Mazzarelli et al. (1995) , highlights further similarity of this viral oncoprotein with adenovirus E1A and SV40 LT, which also bind TBP and activate transcription. Although the principal TBP-binding site in E1A lies within CR3, sequences which are not clearly conserved within E7, lower-affinity TBP binding by E1A which is independent of CR3 has also been noted (Lee et al., 1991) . Mutational analysis suggests that three regions of E7 contribute to the interaction with TBP ; the pRB binding domain (amino acids 24 and 26), the casein kinase II site (amino acids 31\32) and the C-terminal dimerization domain (amino acids 58\91). Mutation within a single region showed only a limited effect on binding with TBP, but alteration within all three completely abolished the interaction.
It has been suggested that pRB binds transcription factors by virtue of its sequence similarity with TBP and TFIIB (Hagemeier et al., 1993) , and proteins that bind pRB may interact with TBP through similar binding sites. Our data suggest that the major pRB binding region of E7 in CR2 contributes to the interaction with TBP and it is of interest that the C terminus of E7, which also contributes to TBP binding, has been shown to contain a low-affinity pRB-binding site (Stirdivant et al., 1992) . These results suggest that the sequence similarity between pRB and TBP may allow E7 to interact with both of these proteins. Nevertheless, unlike the interaction of E7 with pRB, phosphorylation of E7 by CKII appears to enhance the affinity of the viral protein for TBP, as also recently observed by Massimi et al. (1996) . Phosphorylation by CKII has been shown to enhance the transforming activity of E7, although it does not affect pRB binding, and these studies provide an intriguing correlation between transforming efficiency and interaction with TBP.
A recent study of the transcriptional activity of E7 in yeast has revealed two separable transactivation domains of E7, in the N terminus and C terminus of the protein (Zwerschke et al., 1996) , which correlate well with the TBP-binding domains described here. Although transcriptional activity of E7 can be very sensitive to mutations within the cysteine residues in the C-terminal domain (Clemens et al., 1995) , other workers have shown that in the context of a LexA fusion, the 58\91 mutant retained transcriptional activity (Zwershke et al., 1966) . These data suggest that the E7-TBP interaction might contribute to the transcriptional activity of E7.
